Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with unilateral or bilateral intermittent leg claudication which was stable for the last 6 months.~* Patients with ABPI \< 0.9 at rest at least in one leg.~* BP ≤ 160/90 and a stable medication regimen for the last 6 months.~* Able to give informed consent~* Able to comply with study protocol~Exclusion Criteria:~* Documented bilateral renal artery stenosis~* Unlikely to be compliant with medication or follow up as determined by the recruiting institution.~* Pregnancy~* Patients with critical limb ischemia (This includes patients with ischaemic rest pain and ulceration \> 2 weeks and/or a resting ankle pressure \< 50mmHg- Grades II and III according to Rutherford et al 1997.\[56\].~* Patients who had a recent (less than 3 months) angioplasty or bypass surgery~* Patients who are unable to perform a treadmill test due to a limiting heart, respiratory or arthritic disease~* History of angioneurotic oedema~* Currently taking ACE inhibitor or Angiotensin receptor blocker~* Contraindication to ACE inhibitor~* History of ACE inhibitor intolerance~* A creatinine rise of \> 30% from baseline and/or Potassium \> 5.9 mmol/l~* Unwillingness to participate.~* Level 1 evidence for ACE inhibitor treatment, including:~* Documented heart failure, left ventricular dysfunction or ejection fraction \<35% on previous echocardiography~  * Uncontrolled hypertension, BP \> 160mmHg systolic or 100mmHg diastolic on 3 separate readings measured after 10 minutes rest on 2 separate occasions~ * Recent (\< 3months) myocardial infarction or stroke~ * Chronic renal impairment (serum creatinine \> 250 micromol/l)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ramipril (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).